Skip to main content

Advertisement

Table 4 Characteristics and outcomes for patients who completed the exit interview—Southern Malawi, 2015

From: Health worker adherence to malaria treatment guidelines at outpatient health facilities in southern Malawi following implementation of universal access to diagnostic testing

  n/N Weighted percent (95% CI)
Demographics (years)
 <5  723/2342 28.3 (21.8, 34.8)
 ≥5  1619/2342 71.7 (65.2, 78.2)
Suspect malaria classification
 Suspect malaria cases (both uncomplicated and severe) 1695/2342 73.4 (70.2, 76.6)
 Suspect uncomplicated malaria 1605/1695 95.4 (94.2, 96.6)
 Suspect severe malaria 90/1695 4.6 (3.4, 5.8)
Symptoms spontaneously reported to HW by suspect malaria patients
 Fever 1146/1695 68.5 (64.0, 73.0)
 When patient did not spontaneously report fever, HW asked about fever 295/549 51.6 (46.0, 57.2)
 Headache 553/1695 33.4 (28.6, 38.2)
 Vomiting 284/1695 16.9 (14.3, 19.5)
 Skin problem 99/1695 5.5 (3.9, 6.9)
Testing for suspect uncomplicated malaria patients who attended HFs with diagnostic tests
 Tested by either microscopy or RDT 1072/1427 75.7 (68.9, 82.5)
 Positive RDT or microscopy 547/1072 53.2 (46.0, 60.4)
Medications administered, prescribed or dispensed to confirmed uncomplicated malaria patients
 Treated with first- or second-line antimalarial (AM)a 511/547 92.7 (85.4, 99.9)
 Treated with other anti-malarialb 12/547 4.7 (0.0, 11.9)
 No anti-malarial 24/547 2.6 (1.2, 4.0)
Medications administered, prescribed or dispensed to presumed uncomplicated malaria patients
 Treated with first- or second-line AMa 98/178 60.3 (45.1, 75.5)
 Treated with other anti-malarialc 5/178 2.8 (0.0, 8.3)
 No anti-malarial 75/178 36.8 (22.8, 50.8)
Suspect severe malaria
 Received recommended pre-referral anti-malariald 8/90 5.7 (0.3, 11.0)
 Referred or told to get in-patient admission right away 11/90 6.9 (1.9, 11.9)
 Received pre-referral anti-malarial plus immediate referral/admission 3/90 1.6 (0.0, 3.6)
 Treated with other anti-malariale 46/90 59.6 (46.4, 72.8)
 No anti-malarial 36/90 34.7 (22.4, 47.0)
  1. aFirst- or second-line AM refers to artemether-lumefantrine (AL) or artesunate-amodiaquine (ASAQ) for all except pregnant women in first trimester and children weighing <5 kg who get quinine. Numerator includes eight confirmed malaria patients who got both AL and intramuscular (IM) quinine and one confirmed malaria patient who got both AL and IM artesunate
  2. bOral quinine (n = 6), IM quinine (n = 3), AL to women in first trimester (n = 2), SP (n = 1)
  3. cAll given sulfadoxine-pyrimethamine (SP) none of whom was pregnant
  4. dThree received IM artesunate, five received IM quinine
  5. e42 patients received only AL, one received both AL and SP, one received ASAQ and two received oral quinine